The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
Abstract
Several studies have shown that interleukin 6 (IL-6) is a multifunctional cytokine with both pro-inflammatory and anti-inflammatory activity, depending on the immune response context. Macrophages are among several cells that secrete IL-6, which they express upon activation by antigens, subsequently inducing fever and production of acute-phase proteins from the liver. Moreover, IL-6 induces the final maturation of B cells into memory B cells and plasma cells as well as an adaptive role for short-term energy allocation. Activation of IL-6 receptors results in the intracellular activation of the JAK/STAT pathway with resultant production of inflammatory cytokines. Several mechanisms-controlled IL-6 expression, but aberrant production was shown to be crucial in the pathogenesis of many diseases, which include autoimmune and chronic inflammatory diseases. IL-6 in combination with transforming growth factor β (TGF-β) induced differentiation of naïve T cells to Th17 cells, which is the cornerstone in autoimmune diseases. Recently, IL-6 secretion was shown to form the backbone of hypercytokinemia seen in the Coronavirus disease 2019 (COVID-19)-associated hyperinflammation and multiorgan failure. There are two classes of approved IL-6 inhibitors: anti-IL-6 receptor monoclonal antibodies (e.g., tocilizumab) and anti-IL-6 monoclonal antibodies (i.e., siltuximab). These drugs have been evaluated in patients with rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19 who have systemic inflammation. JAK/STAT pathway blockers were also successfully used in dampening IL-6 signal transduction. A better understanding of different mechanisms that modulate IL-6 expression will provide the much-needed solution with excellent safety and efficacy profiles for the treatment of autoimmune and inflammatory diseases in which IL-6 derives their pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V, Yudkin, J. S., Humphries, S., & Woo, P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2629 · Cited by 2,243
Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139
Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
IL‐6: Regulator of Treg/Th17 balance
Kimura, A., & Kishimoto, T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040391 · Cited by 1,595
Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X. F., & Achong, M. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1368 · Cited by 1,498
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Kishimoto, T., Taga, T., & Akira, S. (1994) · Cell · doi:10.1016/0092-8674(94)90333-6 · Cited by 1,328
Structure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
IL-6 switches the differentiation of monocytes from dendritic cells to macrophages
Chomarat, P., Banchereau, J., Davoust, J., & Karolina Palucka, A. (2000) · Nature Immunology · doi:10.1038/82763 · Cited by 906
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV
Moore, P. S., Boshoff, C., Weiss, R. A., & Chang, Y. (1996) · Science · doi:10.1126/science.274.5293.1739 · Cited by 904
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
The two faces of IL-6 on Th1/Th2 differentiation
Diehl, S., & Rincón, M. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00210-9 · Cited by 872
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation
Kaplanski, G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00013-3 · Cited by 811
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Interleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. D. M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., et al. (2021) · JAMA · doi:10.1001/jama.2021.11330 · Cited by 678
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Karell, K., Louka, A. S., Moodie, S. J., Ascher, H., Clot, F., Greco, L., Ciclitira, P. J., Sollid, L. M., & Partanen, J. (2003) · Human Immunology · doi:10.1016/s0198-8859(03)00027-2 · Cited by 613
Becker, K. L., Snider, R., & Nylen, E. S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318165babb · Cited by 598
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Molecular Regulation of B Lymphocyte Response
Kishimoto, T., & Hirano, T. (1988) · Annual Review of Immunology · doi:10.1146/annurev.iy.06.040188.002413 · Cited by 567
The pathogenicity of Th17 cells in autoimmune diseases
Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00733-8 · Cited by 555
The origins, function, and regulation of T follicular helper cells
Ma, C. S., Deenick, E. K., Batten, M., & Tangye, S. G. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120994 · Cited by 552
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 474
Waage, A., Halstensen, A., Shalaby, R., Brandtzaeg, P., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.1859 · Cited by 454
Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
Mudter, J., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20148 · Cited by 436
The role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424
S100 Proteins As an Important Regulator of Macrophage Inflammation
Xia, C., Braunstein, Z., Toomey, A. C., Zhong, J., & Rao, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01908 · Cited by 424
Versatile functions for IL-6 in metabolism and cancer
Mauer, J., Denson, J. L., & Brüning, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.008 · Cited by 407
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller-Newen, G., Grötzinger, J., Rose-John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 400
Mino, T., Murakawa, Y., Fukao, A., Vandenbon, A., Wessels, H.-H., Ori, D., Uehata, T., Tartey, S., Akira, S., Suzuki, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.029 · Cited by 390
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Heink, S., Yogev, N., Garbers, C., Herwerth, M., Aly, L., Gasperi, C., Husterer, V., Croxford, A. L., Möller-Hackbarth, K., Bartsch, H. S., et al. (2017) · Nature Immunology · doi:10.1038/ni.3632 · Cited by 386
Interleukin-6 as a Therapeutic Target
Rossi, J.-F., Lu, Z.-Y., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 366
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Nguyen, D. P., Li, J., & Tewari, A. K. (2014) · BJU International · doi:10.1111/bju.12452 · Cited by 359
Chakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A., & Maihle, N. J. (1992) · Cytokine · doi:10.1016/1043-4666(92)90043-q · Cited by 316
Choi, Y. S., Eto, D., Yang, J. A., Lao, C., & Crotty, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203032 · Cited by 307
IL-6 signalling pathways and the development of type 2 diabetes
Akbari, M., & Hassan-Zadeh, V. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0458-0 · Cited by 302
Schreiber, S., Aden, K., Bernardes, J. P., Conrad, C., Tran, F., Höper, H., Volk, V., Mishra, N., Blase, J. I., Nikolaus, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.062 · Cited by 259
The role of Toll-like receptors in rheumatoid arthritis
Huang, Q.-Q., & Pope, R. M. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0051-z · Cited by 246
Lescure, F.-X., Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., Patel, N., Hagino, O., Bazzalo, I. J., Casas, M. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00099-0 · Cited by 246
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H., & Rigas, J. R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.627850 · Cited by 243
Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S., Boffini, N., Da Prat, V., Di Terlizzi, G., Lanzillotta, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218122 · Cited by 236
Regulation of IL-6 in Immunity and Diseases
Tanaka, T., Narazaki, M., Masuda, K., & Kishimoto, T. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-024-0921-5_4 · Cited by 235
Systematic review of the association between circulating interleukin-6 (IL-6) and cancer
Heikkilä, K., Ebrahim, S., & Lawlor, D. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.047 · Cited by 232
Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo
Masuda, K., Ripley, B., Nishimura, R., Mino, T., Takeuchi, O., Shioi, G., Kiyonari, H., & Kishimoto, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307419110 · Cited by 226
Yokota, K., Sato, K., Miyazaki, T., Aizaki, Y., Tanaka, S., Sekikawa, M., Kozu, N., Kadono, Y., Oda, H., & Mimura, T. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41666 · Cited by 225
Campanati, A., Marani, A., Martina, E., Diotallevi, F., Radi, G., & Offidani, A. (2021) · Biomedicines · doi:10.3390/biomedicines9111511 · Cited by 212
Marin, V., Montero-Julian, F. A., Grès, S., Boulay, V., Bongrand, P., Farnarier, C., & Kaplanski, G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3435 · Cited by 204
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Wouters, M. C. A., Kenter, G. G., van Erkel, A. R., van Poelgeest, M. I. E., Nijman, H. W., van der Hoeven, J. J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv309 · Cited by 197
Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir
HIRANO, T. (2010) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.86.717 · Cited by 172
The soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Tocilizumab: A Review of its Use in the Management of Rheumatoid Arthritis
Oldfield, V., Dhillon, S., & Plosker, G. L. (2009) · Drugs · doi:10.2165/00003495-200969050-00007 · Cited by 165
Yang, R., Masters, A. R., Fortner, K. A., Champagne, D., Yanguas‐Casás, N., Silberger, D. J., Weaver, C. T., Haynes, L., & Rincón, M. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160417 · Cited by 165
Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis
Takeuchi, T., Yoshida, H., & Tanaka, S. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102884 · Cited by 158
Riegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 157
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
Atal, S., & Fatima, Z. (2020) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00342-z · Cited by 155
Brocke-Heidrich, K., Kretzschmar, A. K., Pfeifer, G., Henze, C., Löffler, D., Koczan, D., Thiesen, H., Burger, R., Gramatzki, M., & Horn, F. (2003) · Blood · doi:10.1182/blood-2003-04-1048 · Cited by 154
Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 148
Jones, G. W., & Jones, S. A. (2015) · Immunology · doi:10.1111/imm.12554 · Cited by 146
Molecular and functional heterogeneity of IL-10-producing CD4+ T cells
Brockmann, L., Soukou, S., Steglich, B., Czarnewski, P., Zhao, L., Wende, S., Bedke, T., Ergen, C., Manthey, C., Agalioti, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07581-4 · Cited by 144
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Is IL-6 a key cytokine target for therapy in COVID-19?
Jones, S. A., & Hunter, C. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00553-8 · Cited by 139
KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways
Osborne, J., Moore, P. S., & Chang, Y. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00083-x · Cited by 138
Systemic sclerosis in adults. Part I: Clinical features and pathogenesis
Jerjen, R., Nikpour, M., Krieg, T. M., Denton, C. P., & Saracino, A. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.10.065 · Cited by 138
Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
Riethmueller, S., Somasundaram, P., Ehlers, J. C., Hung, C.-W., Flynn, C. M., Lokau, J., Agthe, M., Düsterhöft, S., Zhu, Y., Grötzinger, J., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2000080 · Cited by 135
Venkiteshwaran, A. (2009) · mAbs · doi:10.4161/mabs.1.5.9497 · Cited by 132
Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma
Kitaba, S., Murota, H., Terao, M., Azukizawa, H., Terabe, F., Shima, Y., Fujimoto, M., Tanaka, T., Naka, T., Kishimoto, T., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.013 · Cited by 131
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
Marfella, R., Paolisso, P., Sardu, C., Bergamaschi, L., D’Angelo, E. C., Barbieri, M., Rizzo, M. R., Messina, V., Maggi, P., Coppola, N., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.005 · Cited by 131
The biology and mechanism of action of Suppressor of Cytokine Signaling 3 (SOCS3)
Babon, J., & Nicola, N. (2012) · Growth Factors · doi:10.3109/08977194.2012.687375 · Cited by 121
Khanna, D., Lescoat, A., Roofeh, D., Bernstein, E. J., Kazerooni, E. A., Roth, M. D., Martínez, F. J., Flaherty, K. R., & Denton, C. P. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41933 · Cited by 120
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 116
Hundhausen, C., Roth, A., Whalen, E., Chen, J., Schneider, A., Long, S. A., Wei, S., Rawlings, R., Kinsman, M., Evanko, S. P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9943 · Cited by 116
Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
Hennigan, S., & Kavanaugh, A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3470 · Cited by 110
Horneff, G., Schulz, A. C., Klotsche, J., Hospach, A., Minden, K., Foeldvari, I., Trauzeddel, R., Ganser, G., Weller‐Heinemann, F., & Haas, J.-P. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1462-2 · Cited by 110
Sun, L., Li, M., Ma, X., Feng, H., Song, J., Lv, C., & He, Y. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1008-1 · Cited by 107
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
Niu, Q., Huang, Z., Wu, X., Jin, Y., An, Y., Li, Y., Xu, H., Yang, B., & Wang, L. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1690-0 · Cited by 105
Song, L., Smith, M. A., Doshi, P. D., Sasser, K., Fulp, W. J., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 104
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease
Samaee, H., Mohsenzadegan, M., Ala, S., Maroufi, S. S., & Moradimajd, P. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107018 · Cited by 103
Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
Lamb, Y. N., & Deeks, E. D. (2018) · Drugs · doi:10.1007/s40265-018-0929-z · Cited by 100
Tocilizumab for the treatment of rheumatoid arthritis
Tanaka, T., Ogata, A., & Narazaki, M. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.70 · Cited by 99
Agasing, A. M., Wu, Q., Khatri, B., Borisow, N., Ruprecht, K., Brandt, A. U., Gawde, S., Kumar, G., Quinn, J. L., Ko, R. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16625-7 · Cited by 98
Setiadi, A. F., Abbas, A. R., Jeet, S., Wong, K., Bischof, A., Peng, I., Lee, J., Bremer, M. C. D., Eggers, E. L., DeVoss, J., et al. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.04.011 · Cited by 92
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond
Karkhur, S., Hasanreisoğlu, M., Vigil, E. M., Halim, M. S., Hassan, M., Plaza, C., Nguyen, N. V., Afridi, R., Tran, A. N. T., Diana, V., et al. (2019) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-019-0182-y · Cited by 88
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis
Bassi, M. S., Iezzi, E., Drulovic, J. S., Pekmezovic, T. D., Gilio, L., Furlan, R., Finardi, A., Marfia, G. A., Sica, F., Centonze, D., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00120 · Cited by 88
Shinriki, S., Jono, H., Ueda, M., Ota, K., Ota, T., Sueyoshi, T., Oike, Y., Ibusuki, M., Hiraki, A., Nakayama, H., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2935 · Cited by 84
Dufour, A. M., Alvarez, M., Russo, B. F., & Chizzolini, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01865 · Cited by 80
Recent developments in MOG-IgG associated neurological disorders
Hegen, H., & Reindl, M. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420945135 · Cited by 77
Wang, D., Fu, B., Peng, Z., Yang, D., Han, M., Li, M., Yang, Y., Yang, T., Sun, L., Li, W., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0824-3 · Cited by 77
Mori, Y., Nishimoto, N., Ohno, M., Inagi, R., Dhepakson, P., Amou, K., Yoshizaki, K., & Yamanishi, K. (2000) · Journal of Medical Virology · Cited by 74
Shieh, J., Tseng, H., Jung, F., Yang, S., & Lin, J. (2019) · Mediators of Inflammation · doi:10.1155/2019/7947596 · Cited by 74
Hudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71
Autoimmunity in vitiligo: Therapeutic implications and opportunities
Khaitan, B. K., & Sindhuja, T. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102932 · Cited by 67
Alraouji, N. N., Almohanna, F., Ghebeh, H., Arafah, M., Almeer, R., Al‐Tweigeri, T., & Aboussekhra, A. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23234 · Cited by 65
IL-6 receptor and mechanism of signal transduction
Kishimoto, T., Akira, S., & Taga, T. (1992) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(92)90173-i · Cited by 64
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
Avcı, A. B., Feist, E., & Burmester, G. R. (2018) · BioDrugs · doi:10.1007/s40259-018-0320-3 · Cited by 63
Bassi, M. S., Iezzi, E., Mori, F., Simonelli, I., Gilio, L., Buttari, F., Sica, F., Paolis, N. D., Mandolesi, G., Musella, A., et al. (2019) · Neurorehabilitation and neural repair · doi:10.1177/1545968319868713 · Cited by 63
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
Greenbaum, C. J., Serti, E., Lambert, K., Weiner, L. J., Kanaparthi, S., Lord, S. M., Gitelman, S. E., Wilson, D. M., Gaglia, J. L., Griffin, K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150074 · Cited by 62
Higa, M., Oka, M., Fujihara, Y., Masuda, K., Yoneda, Y., & Kishimoto, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719921115 · Cited by 61
Pietrzak, A., Chabros, P., Grywalska, E., Pietrzak, D., Kandzierski, G., Wawrzycki, B., Roliński, J., Gawęda, K., & Krasowska, D. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2018.78028 · Cited by 61
Poplutz, M. K., Weßels, I., Rink, L., & Uciechowski, P. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.03.016 · Cited by 57
Tanaka, R., Ichimura, Y., Kubota, N., Saito, A., Nakamura, Y., Ishitsuka, Y., Watanabe, R., Fujisawa, Y., Kanzaki, M., Mizuno, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01308-2 · Cited by 57
Yokota, S., Tanaka, T., & Kishimoto, T. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12455960 · Cited by 56
Hou, H., Wang, C., Sun, F., Zhao, L., Dun, A., & Sun, Z. (2015) · Inflammation Research · doi:10.1007/s00011-015-0850-9 · Cited by 55
Ngollo, M., Pérez, K., Hammoudi, N., Gorelik, Y., Delord, M., Auzolle, C., Bottois, H., Cazals-Hatem, D. L., Bezault, M., Nancey, S., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac021 · Cited by 54
the TOCICOV-study group, Ruíz‐Antorán, B., Sancho‐López, A., Torres, F., Moreno‐Torres, V., de Abechuco, I. D. P. L., López, P. G., Abad‐Santos, F., Rosso-Fernández, C. M., Aldea‐Perona, A., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00373-8 · Cited by 53
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells
Shin, H. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1447 · Cited by 52
Scheinecker, C., Smolen, J., Yasothan, U., Stoll, J., & Kirkpatrick, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2863 · Cited by 49
Balkrishna, A., Nain, P., Chauhan, A., Sharma, N., Gupta, A., Ranjan, R., & Varshney, A. (2020) · Biomolecules · doi:10.3390/biom10020185 · Cited by 48
Tocilizumab inhibits IL‐8 and the proangiogenic potential of triple negative breast cancer cells
Alraouji, N. N., & Aboussekhra, A. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23270 · Cited by 48
A protective role for autophagy in vitiligo
Bastonini, E., Kovacs, D., Raffa, S., Macchie, M. D., Pacifico, A., Iacovelli, P., Torrisi, M. R., & Picardo, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03592-0 · Cited by 48
Tao, L., Liu, H., & Gong, Y. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03561-4 · Cited by 47
Fejtková, M., Suková, M., Hložková, K., Kramarzová, K. Š., Racková, M., Jakubec, D., Bakardjieva, M., Bloomfield, M., Klocperk, A., Paračková, Z., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26452 · Cited by 47
Mariette, X., Hermine, O., Tharaux, P., Resche‐Rigon, M., Porcher, R., Ravaud, P., Bureau, S., Dougados, M., Tibi, A., Azoulay, E., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00315-5 · Cited by 46
Siltuximab: First Global Approval
Markham, A., & Patel, T. (2014) · Drugs · doi:10.1007/s40265-014-0249-x · Cited by 44
IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis
Lee, E. G., Mickle, B. M., & Gallucci, R. M. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.707700 · Cited by 43
Magni, L., Bouazzi, R., Olmedilla, H. H., Petersen, P. S. S., Tozzi, M., & Novak, I. (2021) · Cells · doi:10.3390/cells10081928 · Cited by 41
Navrátilová, A., Bečvář, V., Baloun, J., Damgaard, D., Nielsen, C. H., Veigl, D., Pavelká, K., Vencovský, J., Šenolt, L., & Cerezo, L. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-85561-3 · Cited by 40
Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?
Cardoneanu, A., Burlui, A., Macovei, L. A., Bratoiu, I., Richter, P., & Rezuş, E. (2022) · Biomedicines · doi:10.3390/biomedicines10020318 · Cited by 40
Wu, Y. L., Liu, L., Bian, C., Diao, Q., Nisar, M. F., Jiang, X., Bartsch, J. W., Zhong, M., Hu, X., & Zhong, J. L. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0271-9 · Cited by 39
Malekzadeh, R., Abedini, A., Mohsenpour, B., Sharifipour, E., Ghasemian, R., Javad‐Mousavi, S. A., Khodashahi, R., Darban, M., Kalantari, S., Abdollahi, N., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107102 · Cited by 39
Ahlers, J., Mantei, A., Lozza, L., Stäber, M., Heinrich, F., Bächer, P., Hohnstein, T., Menzel, L., Yüz, S. G., Álvarez-Simón, D., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00487-x · Cited by 39
von Essen, M. R., Søndergaard, H. B., Petersen, E. R., & Sellebjerg, F. T. (2019) · Cells · doi:10.3390/cells8030285 · Cited by 37
Méndez-Clemente, A. S., Bravo‐Cuéllar, A., Ochoa, S. G., Santiago‐Mercado, M., Palafox-Mariscal, L. A., Jave‐Suárez, L. F., Ibarra, F. S., Villaseñor-García, M. M., Ortiz‐Lazareno, P. C., & Hernández‐Flores, G. (2022) · Oncology Reports · doi:10.3892/or.2022.8349 · Cited by 37
Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis
Singh, M., Jadeja, S. D., Vaishnav, J., Mansuri, M. S., Shah, C., Mayatra, J. M., Shah, A., & Begum, R. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1813756 · Cited by 36
Gokhale, Y. A., Mehta, R., Kulkarni, U. P., Karnik, N., Gokhale, S., Sundar, U., Chavan, S. A., Kor, A., Thakur, S., Trivedi, T. H., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05912-3 · Cited by 36
Ali, F. E. M., Elfiky, M. M., Fadda, W. A., Ali, H. S., Mahmoud, A. R., Mohammedsaleh, Z. M., & Abd‐Elhamid, T. H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119433 · Cited by 36
IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis.
Chen, Y., Ma, Z., Xu, J., Shi, L., Li, D.-Y., Sun, L., Yin, X., Sang, G.-Y., Xu, D., Tang, Y., et al. (2015) · Europe PMC (PubMed Central) · Cited by 35
IL-6 and type 1 diabetes mellitus: T cell responses and increase in IL-6 receptor surface expression
Gomes, K. B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.74 · Cited by 33
Al-Jomah, N. A., Almohanna, F., & Aboussekhra, A. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab102 · Cited by 33
Yoshida, S., Yamada, S., Yokose, K., Matsumoto, H., Fujita, Y., Asano, T., Matsuoka, N., Temmoku, J., Sato, S., Yoshiro-Furuya, M., et al. (2021) · BMC Research Notes · doi:10.1186/s13104-021-05860-w · Cited by 33
Chung, A. W., Kozielski, A. J., Qian, W. P., Zhou, J., Anselme, A. C., Chan, A. A., Pan, P., Lee, D. J., & Chang, J. C. (2022) · npj Breast Cancer · doi:10.1038/s41523-021-00371-0 · Cited by 33
Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities
Abell, T. L., Kedar, A., Stocker, A. M., Beatty, K., McElmurray, L., Hughes, M. G., Rashed, H. M., Kennedy, W. R., Wendelschafer‐Crabb, G., Yang, X. J., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06259-6 · Cited by 32
D’Arino, A., Picardo, M., Truglio, M., Pacifico, A., & Iacovelli, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168820 · Cited by 32
Karataş, A., Öz, B., Celik, C., Akar, Z. A., Akkoç, R. F., Etem, E. Ö., Dağlı, A. F., & Koca, S. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-06581-1 · Cited by 31
Kishimoto, T. (2005) · Clinical reviews in allergy and immunology · doi:10.1385/criai:28:3:177 · Cited by 27
Gao, Y., Jin, H., Nan, D., Yu, W., Zhang, J., Yang, Y., Hou, R., Qin, R., Hao, H.-J., Sun, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56365-3 · Cited by 27
Chan, K. K. L., & Shorey, S. (2021) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2021.12.002 · Cited by 27
Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy
Adler, B. L., Hummers, L. K., Pasricha, P. J., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac074 · Cited by 26
Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
Marıno, A., Munafò, A., Augello, E., Bellanca, C. M., Bonomo, C., Ceccarelli, M., Musso, N., Cantarella, G., Cacopardo, B. S., & Bernardini, R. (2022) · Infectious Disease Reports · doi:10.3390/idr14030040 · Cited by 26
Zarei, S., Eggert, J., Franqui-Dominguez, L., Carl, Y., Boria, F., Stukova, M., Avila, A., Rubí, C., & Chinea, A. R. (2018) · Surgical Neurology International · doi:10.4103/sni.sni_224_18 · Cited by 23
▼Tocilizumab for rheumatoid arthritis
BMJ Publishing Group Ltd (2009) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2009.08.0033 · Cited by 21
Ohsugi, Y. (2019) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2019.100030 · Cited by 17
Tocilizumab: An lnterleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis
Plushner, S. L. (2008) · The Annals of Pharmacotherapy · doi:10.1345/aph.1l268 · Cited by 16
Toda, M., Fujii, K., Yoshifuji, A., Kondo, Y., Itoh, K., Sekine, K., Kikuchi, T., & Ryuzaki, M. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02126-4 · Cited by 16
Singh, A., Danda, D., Hussain, S., Najmi, A. K., Mathew, A. J., Goel, R., Lakhan, S. E., Tajudheen, B., & Antony, B. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1724671 · Cited by 14
Shah, S. R., Shaikh, S. B., Bhandary, Y. P., et al. (2022) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_306_21 · Cited by 13
Clinical Relevance of Liver Involvement in the Clinical Course of Systemic Sclerosis
Lorena, M., Bellan, M., Lepore, M., Sola, D., Pedrazzoli, R., Rigamonti, C., Benedittis, C. D., Manfredi, G. F., Acquaviva, A., Tonello, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040966 · Cited by 11
Maghbooli, Z., Moghadasi, A. N., Rezaeimanesh, N., Omidifar, A., Varzandi, T., & Sahraian, M. A. (2021) · BMC Neurology · doi:10.1186/s12883-021-02198-5 · Cited by 10
Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.933973 · Cited by 10
Tocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients
Guz, D., Gafter‐Gvili, A., Lev, N., Levin, G. S., & Lev, S. (2022) · Acta Haematologica · doi:10.1159/000522307 · Cited by 10
Luckett‐Chastain, L. R., King, C. J., McShan, W. M., Gipson, J. R., Gillaspy, A. F., & Gallucci, R. M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.658980 · Cited by 9
Physiology and Pathology of Cytokine: Commercial Production and Medical Use
Zdravkovic, N. S., Rosic, M. A., Lutovac, M., & Zdravković, V. (2017) · InTech eBooks · doi:10.5772/intechopen.72200 · Cited by 8
Sabe, H., Inoue, A., Nagata, S., Imura, Y., Wakamatsu, T., Takenaka, S., & Tamiya, H. (2021) · Case Reports in Oncological Medicine · doi:10.1155/2021/5532258 · Cited by 8
Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis
Omerzu, T., Magdič, J., Hojs, R., Potočnik, U., Gorenjak, M., & Fabjan, T. H. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01862-7 · Cited by 7
Jang, S., Jang, S., Kim, S., Ko, J., Kim, E., Park, J. Y., Hyung, H., Lee, J. H., Lim, S., Park, S., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s312963 · Cited by 6
Patel, V., Jayaraman, A. K., & Jayaraman, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108490 · Cited by 6
MicroRNA-217 regulates interstitial pneumonia via IL-6
Pan, J., Ye, Z., Zhang, N., Lou, T., & Cao, Z. (2018) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2018.1519379 · Cited by 5
Kang, H., Li, H., Ai, N., Liu, H., Xu, Q.-G., Tao, Y., & Wei, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.589288 · Cited by 5
Aliyu, M., Mozhgani, S., Gargari, O. K., Yusuf, M. A., & Saboor-Yaraghi, A. A. (2021) · AIMS Allergy and Immunology · doi:10.3934/allergy.2021018 · Cited by 2
Self-citation
Cited by
Bone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
Metadata
- Authors
- Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 111
- Pages
- 109130
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4293276053
- Cited by
- 401
- References
- 174
- FWCI
- 25.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.